Overview Dividends

(UHS) Universal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9139031002

Hospitals, Outpatient Centers, Behavioral Health, Surgery, Insurance

UHS EPS (Earnings per Share)

EPS Growth (3Y CAGR): -56.46%
EPS Trend (3Y Correlation): -9.6%

UHS Revenue

Revenue Growth (3Y CAGR): 9.52%
Revenue Trend (3Y Correlation): 99.2%

Description: UHS Universal Health October 30, 2025

Universal Health Services, Inc. (NYSE: UHS) operates a nationwide network of acute-care hospitals and behavioral-health facilities through two segments: Acute Care Hospital Services and Behavioral Health Care Services. Its service portfolio spans general and specialty surgery, obstetrics, emergency care, radiology, oncology, pediatric and coronary care, as well as comprehensive behavioral-health programs, supplemented by ancillary services such as pharmacy, central purchasing, and physician recruitment.

Key financial indicators from the most recent fiscal year show revenue of roughly $9.4 billion and an adjusted operating margin near 7 %, while average hospital occupancy hovers around 78 %, reflecting modest capacity utilization in a market still adjusting to post-pandemic demand dynamics.

Sector-level drivers that materially affect UHS include the aging U.S. population, which fuels higher inpatient and chronic-care utilization, and ongoing Medicare/Medicaid reimbursement reforms that pressure pricing power. Additionally, the industry’s shift toward outpatient and tele-health services creates both growth opportunities and competitive pressures for traditional hospital operators.

For deeper quantitative analysis, the ValueRay platform offers granular cash-flow and valuation metrics that can help assess UHS’s upside.

UHS Stock Overview

Market Cap in USD	13,390m
Sub-Industry	Health Care Facilities
IPO / Inception	1990-03-26

UHS Stock Ratings

Growth Rating	51.9%
Fundamental	72.5%
Dividend Rating	39.9%
Return 12m vs S&P 500	-13.9%
Analyst Rating	3.79 of 5

UHS Dividends

Dividend Yield 12m	0.37%
Yield on Cost 5y	0.72%
Annual Growth 5y	41.42%
Payout Consistency	56.8%
Payout Ratio	4.3%

UHS Growth Ratios

Growth Correlation 3m	96.5%
Growth Correlation 12m	-1.7%
Growth Correlation 5y	68.4%
CAGR 5y	25.52%
CAGR/Max DD 3y (Calmar Ratio)	0.72
CAGR/Mean DD 3y (Pain Ratio)	2.05
Sharpe Ratio 12m	1.09
Alpha	-17.24
Beta	1.305
Volatility	28.63%
Current Volume	507.9k
Average Volume 20d	536k
Stop Loss	210.4 (-3%)
Signal	0.45

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (1.26b TTM) > 0 and > 6% of Revenue (6% = 987.6m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 0.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 4.09% (prev 3.94%; Δ 0.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 1.90b > Net Income 1.26b (YES >=105%, WARN >=100%)

Net Debt (4.87b) to EBITDA (2.43b) ratio: 2.01 <= 3.0 (WARN <= 3.5)

Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (65.0m) change vs 12m ago -4.31% (target <= -2.0% for YES)

Gross Margin 90.17% (prev 89.58%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 113.3% (prev 106.7%; Δ 6.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 11.43 (EBITDA TTM 2.43b / Interest Expense TTM 160.1m) >= 6 (WARN >= 3)

Altman Z'' 3.86

(A) 0.04 = (Total Current Assets 2.99b - Total Current Liabilities 2.32b) / Total Assets 14.99b

(B) 0.51 = Retained Earnings (Balance) 7.71b / Total Assets 14.99b

(D) 0.99 = Book Value of Equity 7.77b / Total Liabilities 7.84b

Total Rating: 3.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 72.48

1. Piotroski 7.50pt = 2.50

2. FCF Yield 4.94% = 2.47

3. FCF Margin 5.48% = 1.37

4. Debt/Equity 0.71 = 2.25

5. Debt/Ebitda 2.01 = -0.01

6. ROIC - WACC (= 4.31)% = 5.39

7. RoE 18.62% = 1.55

8. Rev. Trend 99.18% = 7.44

9. EPS Trend -9.58% = -0.48

What is the price of UHS shares?

As of November 04, 2025, the stock is trading at USD 217.01 with a total of 507,900 shares traded.
Over the past week, the price has changed by +1.39%, over one month by +5.58%, over three months by +31.92% and over the past year by +4.36%.

Is Universal Health a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Universal Health (NYSE:UHS) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 72.48 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UHS is around 223.67 USD . This means that UHS is currently overvalued and has a potential downside of 3.07%.

Is UHS a buy, sell or hold?

Universal Health has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold UHS.

Strong Buy: 7
Buy: 1
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UHS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	225.1	3.7%
Analysts Target Price	225.1	3.7%
ValueRay Target Price	248.3	14.4%

UHS Fundamental Data Overview October 25, 2025

Market Cap USD = 13.39b (13.39b USD * 1.0 USD.USD)
P/E Trailing = 11.0037
P/E Forward = 9.2081
P/S = 0.8134
P/B = 1.8606
P/EG = 1.87
Beta = 1.305
Revenue TTM = 16.46b USD
EBIT TTM = 1.83b USD
EBITDA TTM = 2.43b USD
Long Term Debt = 4.54b USD (from longTermDebt, last quarter)
Short Term Debt = 114.1m USD (from shortTermDebt, last quarter)
Debt = 5.01b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.87b USD (from netDebt column, last quarter)
Enterprise Value = 18.26b USD (13.39b + Debt 5.01b - CCE 137.6m)
Interest Coverage Ratio = 11.43 (Ebit TTM 1.83b / Interest Expense TTM 160.1m)
FCF Yield = 4.94% (FCF TTM 901.5m / Enterprise Value 18.26b)
FCF Margin = 5.48% (FCF TTM 901.5m / Revenue TTM 16.46b)
Net Margin = 7.66% (Net Income TTM 1.26b / Revenue TTM 16.46b)
Gross Margin = 90.17% ((Revenue TTM 16.46b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 90.22% (prev 90.17%)
Tobins Q-Ratio = 1.22 (Enterprise Value 18.26b / Total Assets 14.99b)
Interest Expense / Debt = 0.69% (Interest Expense 34.5m / Debt 5.01b)
Taxrate = 23.40% (110.8m / 473.4m)
NOPAT = 1.40b (EBIT 1.83b * (1 - 23.40%))
Current Ratio = 1.29 (Total Current Assets 2.99b / Total Current Liabilities 2.32b)
Debt / Equity = 0.71 (Debt 5.01b / totalStockholderEquity, last quarter 7.03b)
Debt / EBITDA = 2.01 (Net Debt 4.87b / EBITDA 2.43b)
Debt / FCF = 5.40 (Net Debt 4.87b / FCF TTM 901.5m)
Total Stockholder Equity = 6.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.41% (Net Income 1.26b / Total Assets 14.99b)
RoE = 18.62% (Net Income TTM 1.26b / Total Stockholder Equity 6.77b)
RoCE = 16.17% (EBIT 1.83b / Capital Employed (Equity 6.77b + L.T.Debt 4.54b))
RoIC = 12.33% (NOPAT 1.40b / Invested Capital 11.37b)
WACC = 8.02% (E(13.39b)/V(18.40b) * Re(10.82%) + D(5.01b)/V(18.40b) * Rd(0.69%) * (1-Tc(0.23)))
Discount Rate = 10.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF Debug] Terminal Value 72.95% ; FCFE base≈874.3m ; Y1≈1.08b ; Y5≈1.84b
Fair Price DCF = 352.5 (DCF Value 19.88b / Shares Outstanding 56.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -9.58 | EPS CAGR: -56.46% | SUE: -4.0 | # QB: 0
Revenue Correlation: 99.18 | Revenue CAGR: 9.52% | SUE: 0.97 | # QB: 1

Additional Sources for UHS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle